Clinical Cases in Pharmacology Clinical Cases  ·  Anesthesiology Vol. III  ·  Pediatric Anesthesiology  ·  Dexamethasone Before Tonsillectomy: The PONV Benefit Is Real, But So Is the Bleeding Question
Anesthesiology Vol. III, Case 0007 — Pediatric Anesthesiology

Dexamethasone Before Tonsillectomy: The PONV Benefit Is Real, But So Is the Bleeding Question

A single patient about to receive a drug nearly every tonsillectomy gets. The disagreement isn't whether dexamethasone reduces vomiting — it clearly does — it's whether the dose being reached for by habit is actually the dose the evidence supports.

Abbreviations, terms, and other agents mentioned in this case PONV — postoperative nausea and vomiting  ·  5-HT3 — serotonin type 3 receptor
Presentation

Toby S. is 8, and this is the surgery his parents have been asking his pediatrician about since his seventh documented episode of tonsillitis this year — the point at which the AAO-HNS guideline stops recommending watchful waiting — a straightforward, well-worn indication, and today's operation is expected to be equally straightforward. The clinical question left to settle before he goes back is one most tonsillectomy patients never hear discussed explicitly, because it usually happens by default: what dose of dexamethasone to give, and why that number and not another one. Dexamethasone before tonsillectomy is close to universal practice for a real reason — a single intraoperative dose reliably and substantially reduces postoperative nausea and vomiting, one of the most common reasons a child ends up readmitted or simply miserable in the first 24 hours after this specific surgery, where swallowing against a nauseated stomach is its own added misery on top of the sore throat itself.

What's less settled, and less often actually discussed at the bedside, is dose. The historical default in many practices crept toward a single fixed dose regardless of weight, often 10mg, extrapolated more from adult PONV-prophylaxis convention than from pediatric-specific dose-finding work. The AAO-HNS guideline strongly recommends that single intraoperative dose but names no number for it, which is exactly why the question is still live at the bedside. The pediatric trial literature has largely settled on a weight-based dose around 0.15mg/kg, and for Toby at 26 kilograms that arithmetic matters more than it looks: 0.15mg/kg is 3.9mg, the habitual fixed dose is 10mg, and the higher weight-based figure sometimes quoted, 0.5mg/kg, would be 13mg — more than the fixed dose it is often assumed to undercut. The bleeding question sits underneath all three numbers. Czarnetzki's randomized trial (JAMA, 2008) gave 0.05, 0.15 or 0.5mg/kg and found the antiemetic benefit rose with dose — and so did postoperative bleeding, the only dose-dependent bleeding signal in this literature, and it sat at the 0.5mg/kg arm. Larger observational work since, including a 2,788-child review from Massachusetts Eye and Ear, has not reproduced a dose-dependent bleeding effect after adjustment. So the reassurance is real but it is retrospective, and the one randomized signal points at the top of the dose range rather than away from it.

Toby S. · 8 Elective Tonsillectomy
Indication
Recurrent tonsillitis, seven documented episodes in twelve months
PONV risk factors
Age over 3, procedure with high baseline PONV incidence (tonsillectomy itself), no personal history of motion sickness or prior PONV
Bleeding risk factors
None identified; no personal or family history
Weight
26 kg
Surgical plan
Standard cold-steel tonsillectomy, no adenoidectomy needed this time
Prior surgery
None

Preoperative order review, morning of surgery

Clinical Pharmacologist Opening

I'd give 0.15mg/kg here — for Toby that's under 4mg — rather than the 10mg that defaults onto some of these order sets, and rather than 0.5mg/kg. I want to be careful about a claim I hear made in the other direction, that weight-based dosing is automatically the lower, safer choice. At 26 kilograms it isn't: 0.5mg/kg would be 13mg, more than the fixed dose. The number that matters is the actual milligram total, not whether it was reached by weight.

And the one randomized bleeding signal we have, Czarnetzki's, sat at the 0.5mg/kg arm. That's the dose I'd most want to avoid in a surgery whose feared complication is bleeding, which makes 0.15mg/kg the better-evidenced choice on both counts at once rather than a compromise between them.

Otolaryngologist Response

I hear the dosing argument, and I'd point out that the same trial you're citing cuts both ways. Czarnetzki found the antiemetic effect rose with dose too — 0.5mg/kg didn't just bleed more, it worked better. Undertreated PONV after tonsillectomy is common and miserable, and I see it in my own patients when prophylaxis falls short: vomiting against a fresh surgical bed, on top of throat pain already making swallowing hard.

I don't think 'adequately effective' in a trial population automatically means adequately effective for every individual child, and I'd rather not find out Toby's the exception at the cost of a bad first night.

Pediatric Anesthesiologist Final

For Toby specifically, I'd go with 0.15mg/kg — he has no PONV history suggesting he needs the higher end of anything, and I'd rather not buy a marginal antiemetic gain at the one dose where a randomized trial actually found more bleeding. But I want to flag something beyond today's case: this exact disagreement will recur every time a different team is on this room, and it shouldn't have to.

I'd propose taking this to the department's order-set review, so the weight-based dose becomes the default rather than something each team re-derives from memory of the literature under time pressure before a case.

Regimen selected
Dexamethasone
Corticosteroid · Weight-based dosing (0.15mg/kg, ~3.9mg)
Given at 0.15mg/kg, the dose the pediatric antiemetic trials have largely settled on, chosen over both the habitual fixed 10mg and the 0.5mg/kg arm where Czarnetzki's dose-dependent bleeding signal was found. At 26kg, 0.5mg/kg would be 13mg — higher, not lower, than the fixed dose.
Ondansetron
5-HT3 Antagonist · Adjunct antiemetic
Added as a second antiemetic agent acting through a distinct mechanism, per standard multimodal PONV prophylaxis practice for a high-risk procedure.
Where this was left

Dexamethasone 0.15mg/kg (3.9mg) given intraoperatively alongside ondansetron; anesthesiologist to raise the dosing inconsistency at the next department order-set review.

Not agreed, and the reason the plan carries an explicit branch point rather than a single expectation:

If Toby has a smooth, low-nausea recovery

The case is documented as further support for 0.15mg/kg as adequate, adding to the pharmacologist's evidentiary case for the order-set change.

If Toby has significant PONV despite the 0.15mg/kg dose

The otolaryngologist's concern about individual under-response would be revisited directly, and a higher rescue-dose protocol considered for future similar patients.

Whether the order-set should actually be changed institution-wide — that decision sits with the department review the anesthesiologist proposed to raise, not with this individual case's own team, and remains genuinely undecided pending that separate conversation.

Educational content only — a composite teaching case, not a real patient encounter or a substitute for clinical guidance. About These Cases →